Global Cannabidiol research
Global Cannabidiol research

Cannabidiol Comprehensive Study by Type (Food Grade, Pharmaceutical Grade), Application (Medical, Recreational), Disease Indication (Anxiety, Fibromyalgia (FM), Diabetes, Other) Players and Region - Global Market Outlook to 2024

Cannabidiol Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Sep 2019 Edition 214 Pages 172 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Cannabidiol Market Overview:
Cannabidiol (CBD) is one of the hundreds of cannabinoids that are found in the cannabis plant. This is a naturally occurring substance, can be extracted & mixed with a carrier oil, often hemp seed or coconut, to create CBD oil. Cannabidiol oil can be derived from two different species of cannabinoids such as marijuana and hemp. Rising awareness about the health benefits of Cannabidiol is the major factors that are expected to drive the growth of the global Cannabidiol market. The demand for Cannabidiol is increasing around the globe owing to their capacity to cure various ailments in the human body. Cannabidiol in the form of CBD oil is used for the protection from Alzheimer's disease and has anti-inflammatory properties. It also benefits in the treatment of epilepsy and mental health disorders. The adoption rate of Cannabidiol is increasing because they help in drug withdrawal. It is highly recommended, as it can suppress the growth of cancer cells to prevent cancer. Some of the key players profiled in the study are ENDOCA BV (Netherlands), CBD American Shaman (United States), Isodiol International Inc. (Canada), Medical Marijuana Inc. (United States), Aurora Cannabis Inc. (Canada), Cannoid LLC (United States), Canopy Growth Corporation (Canada), CV Sciences, Inc. (United States), Elixinol LLC (United States) and NuLeaf Naturals, LLC. (United States).

On the basis of geography, the market of Cannabidiol has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease Indication, the sub-segment i.e. Anxiety will boost the Cannabidiol market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing Awareness Regarding Health benefits of CBD oil
  • Globally Increasing Millennial Population and Rising E-Commerce Industry

Market Trend
  • Increasing Legalization of Cannabis-Based Products
  • Legalization of Cannabis for Medicinal and Recreational Activities

Restraints
  • High Cost of the Product
  • Availability of Low Yield

Opportunities
  • Emerging Markets and The advent of advanced cultivation processes
  • Growing Investments made for the Production of Cannabis Oil

Challenges
  • Lack of Harvesting Innovations and Processing Facilities
  • Strict Government Regulations in Some Countries


Major Market Developments:

March 4, 2019: Aurora Completes Whistler Medical Acquisition. The Transaction provides Aurora with a premium and differentiated organic certified product suite, expanding both its medical and consumer offerings, and reinforcing Aurora's presence in the well-established west coast cannabis market.
On 21 Jan. 2019, Canopy Growth Corporation has announced the expansion of its business in the European regions such as the United Kingdom and Poland where its medically-focused business Spectrum Cannabis continues to build a sophisticated, pan-European cannabis production as well as distribution network serving the needs of physicians and their patients throughout the continent.
In the United States, Food and Drug Administration approved the CBD drug Epidiolex for treatment of two epilepsy disorders. Also, The U.S. Drug Enforcement Administration (DEA) has assigned Epidiolex a Schedule V classification as well as non-Epidiolex CBD remains a Schedule I drug prohibited for any usage. In 2018, the World Health Organization recommended that CBD remain unscheduled. CBD is not scheduled under any United Nations drug control treaties.
The companies are exploring the market in new regions by adopting mergers & acquisitions, expansions, investments and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Target Audience:
Cannabidiol Products manufacturers, Raw material suppliers, Hospitals, Government and research organizations, Distribution consultancies and End users

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Cannabidiol market on the basis of product [Food Grade and Pharmaceutical Grade] , application [Medical and Recreational], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Cannabidiol market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Cannabidiol industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are FOLIUM BIOSCIENCES (United States), Green Roads Wellness (United States), Kazmira LLC (Orochem Technologies) (United States) and Charlotte's Web (CWB Holdings, Inc.) (United States).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Cannabidiol market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Type
  • Food Grade
  • Pharmaceutical Grade
By Application
  • Medical
  • Recreational
By Disease Indication
  • Anxiety
  • Fibromyalgia (FM)
  • Diabetes
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Awareness Regarding Health benefits of CBD oil
      • 3.2.2. Globally Increasing Millennial Population and Rising E-Commerce Industry
    • 3.3. Market Challenges
      • 3.3.1. Lack of Harvesting Innovations and Processing Facilities
      • 3.3.2. Strict Government Regulations in Some Countries
    • 3.4. Market Trends
      • 3.4.1. Increasing Legalization of Cannabis-Based Products
      • 3.4.2. Legalization of Cannabis for Medicinal and Recreational Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cannabidiol, by Type, Application, Disease Indication and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Cannabidiol (Value)
      • 5.2.1. Global Cannabidiol by: Type (Value)
        • 5.2.1.1. Food Grade
        • 5.2.1.2. Pharmaceutical Grade
      • 5.2.2. Global Cannabidiol by: Application (Value)
        • 5.2.2.1. Medical
        • 5.2.2.2. Recreational
      • 5.2.3. Global Cannabidiol by: Disease Indication (Value)
        • 5.2.3.1. Anxiety
        • 5.2.3.2. Fibromyalgia (FM)
        • 5.2.3.3. Diabetes
        • 5.2.3.4. Other
      • 5.2.4. Global Cannabidiol Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Cannabidiol (Volume)
      • 5.3.1. Global Cannabidiol by: Type (Volume)
        • 5.3.1.1. Food Grade
        • 5.3.1.2. Pharmaceutical Grade
      • 5.3.2. Global Cannabidiol by: Application (Volume)
        • 5.3.2.1. Medical
        • 5.3.2.2. Recreational
      • 5.3.3. Global Cannabidiol by: Disease Indication (Volume)
        • 5.3.3.1. Anxiety
        • 5.3.3.2. Fibromyalgia (FM)
        • 5.3.3.3. Diabetes
        • 5.3.3.4. Other
      • 5.3.4. Global Cannabidiol Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Cannabidiol (Price)
      • 5.4.1. Global Cannabidiol by: Type (Price)
  • 6. Cannabidiol: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ENDOCA BV (Netherlands)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CBD American Shaman (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Isodiol International Inc. (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Medical Marijuana Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Aurora Cannabis Inc. (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cannoid LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Canopy Growth Corporation (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. CV Sciences, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Elixinol LLC (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. NuLeaf Naturals, LLC. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cannabidiol Sale, by Type, Application, Disease Indication and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Cannabidiol (Value)
      • 7.2.1. Global Cannabidiol by: Type (Value)
        • 7.2.1.1. Food Grade
        • 7.2.1.2. Pharmaceutical Grade
      • 7.2.2. Global Cannabidiol by: Application (Value)
        • 7.2.2.1. Medical
        • 7.2.2.2. Recreational
      • 7.2.3. Global Cannabidiol by: Disease Indication (Value)
        • 7.2.3.1. Anxiety
        • 7.2.3.2. Fibromyalgia (FM)
        • 7.2.3.3. Diabetes
        • 7.2.3.4. Other
      • 7.2.4. Global Cannabidiol Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Cannabidiol (Volume)
      • 7.3.1. Global Cannabidiol by: Type (Volume)
        • 7.3.1.1. Food Grade
        • 7.3.1.2. Pharmaceutical Grade
      • 7.3.2. Global Cannabidiol by: Application (Volume)
        • 7.3.2.1. Medical
        • 7.3.2.2. Recreational
      • 7.3.3. Global Cannabidiol by: Disease Indication (Volume)
        • 7.3.3.1. Anxiety
        • 7.3.3.2. Fibromyalgia (FM)
        • 7.3.3.3. Diabetes
        • 7.3.3.4. Other
      • 7.3.4. Global Cannabidiol Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Cannabidiol (Price)
      • 7.4.1. Global Cannabidiol by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cannabidiol: by Type(USD Million)
  • Table 2. Cannabidiol Food Grade , by Region USD Million (2013-2018)
  • Table 3. Cannabidiol Pharmaceutical Grade , by Region USD Million (2013-2018)
  • Table 4. Cannabidiol: by Application(USD Million)
  • Table 5. Cannabidiol Medical , by Region USD Million (2013-2018)
  • Table 6. Cannabidiol Recreational , by Region USD Million (2013-2018)
  • Table 7. Cannabidiol: by Disease Indication(USD Million)
  • Table 8. Cannabidiol Anxiety , by Region USD Million (2013-2018)
  • Table 9. Cannabidiol Fibromyalgia (FM) , by Region USD Million (2013-2018)
  • Table 10. Cannabidiol Diabetes , by Region USD Million (2013-2018)
  • Table 11. Cannabidiol Other , by Region USD Million (2013-2018)
  • Table 12. South America Cannabidiol, by Country USD Million (2013-2018)
  • Table 13. South America Cannabidiol, by Type USD Million (2013-2018)
  • Table 14. South America Cannabidiol, by Application USD Million (2013-2018)
  • Table 15. South America Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 16. Brazil Cannabidiol, by Type USD Million (2013-2018)
  • Table 17. Brazil Cannabidiol, by Application USD Million (2013-2018)
  • Table 18. Brazil Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 19. Argentina Cannabidiol, by Type USD Million (2013-2018)
  • Table 20. Argentina Cannabidiol, by Application USD Million (2013-2018)
  • Table 21. Argentina Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 22. Rest of South America Cannabidiol, by Type USD Million (2013-2018)
  • Table 23. Rest of South America Cannabidiol, by Application USD Million (2013-2018)
  • Table 24. Rest of South America Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 25. Asia Pacific Cannabidiol, by Country USD Million (2013-2018)
  • Table 26. Asia Pacific Cannabidiol, by Type USD Million (2013-2018)
  • Table 27. Asia Pacific Cannabidiol, by Application USD Million (2013-2018)
  • Table 28. Asia Pacific Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 29. China Cannabidiol, by Type USD Million (2013-2018)
  • Table 30. China Cannabidiol, by Application USD Million (2013-2018)
  • Table 31. China Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 32. Japan Cannabidiol, by Type USD Million (2013-2018)
  • Table 33. Japan Cannabidiol, by Application USD Million (2013-2018)
  • Table 34. Japan Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 35. India Cannabidiol, by Type USD Million (2013-2018)
  • Table 36. India Cannabidiol, by Application USD Million (2013-2018)
  • Table 37. India Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 38. South Korea Cannabidiol, by Type USD Million (2013-2018)
  • Table 39. South Korea Cannabidiol, by Application USD Million (2013-2018)
  • Table 40. South Korea Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 41. Taiwan Cannabidiol, by Type USD Million (2013-2018)
  • Table 42. Taiwan Cannabidiol, by Application USD Million (2013-2018)
  • Table 43. Taiwan Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 44. Australia Cannabidiol, by Type USD Million (2013-2018)
  • Table 45. Australia Cannabidiol, by Application USD Million (2013-2018)
  • Table 46. Australia Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 47. Rest of Asia-Pacific Cannabidiol, by Type USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Cannabidiol, by Application USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 50. Europe Cannabidiol, by Country USD Million (2013-2018)
  • Table 51. Europe Cannabidiol, by Type USD Million (2013-2018)
  • Table 52. Europe Cannabidiol, by Application USD Million (2013-2018)
  • Table 53. Europe Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 54. Germany Cannabidiol, by Type USD Million (2013-2018)
  • Table 55. Germany Cannabidiol, by Application USD Million (2013-2018)
  • Table 56. Germany Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 57. France Cannabidiol, by Type USD Million (2013-2018)
  • Table 58. France Cannabidiol, by Application USD Million (2013-2018)
  • Table 59. France Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 60. Italy Cannabidiol, by Type USD Million (2013-2018)
  • Table 61. Italy Cannabidiol, by Application USD Million (2013-2018)
  • Table 62. Italy Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 63. United Kingdom Cannabidiol, by Type USD Million (2013-2018)
  • Table 64. United Kingdom Cannabidiol, by Application USD Million (2013-2018)
  • Table 65. United Kingdom Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 66. Netherlands Cannabidiol, by Type USD Million (2013-2018)
  • Table 67. Netherlands Cannabidiol, by Application USD Million (2013-2018)
  • Table 68. Netherlands Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 69. Rest of Europe Cannabidiol, by Type USD Million (2013-2018)
  • Table 70. Rest of Europe Cannabidiol, by Application USD Million (2013-2018)
  • Table 71. Rest of Europe Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 72. MEA Cannabidiol, by Country USD Million (2013-2018)
  • Table 73. MEA Cannabidiol, by Type USD Million (2013-2018)
  • Table 74. MEA Cannabidiol, by Application USD Million (2013-2018)
  • Table 75. MEA Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 76. Middle East Cannabidiol, by Type USD Million (2013-2018)
  • Table 77. Middle East Cannabidiol, by Application USD Million (2013-2018)
  • Table 78. Middle East Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 79. Africa Cannabidiol, by Type USD Million (2013-2018)
  • Table 80. Africa Cannabidiol, by Application USD Million (2013-2018)
  • Table 81. Africa Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 82. North America Cannabidiol, by Country USD Million (2013-2018)
  • Table 83. North America Cannabidiol, by Type USD Million (2013-2018)
  • Table 84. North America Cannabidiol, by Application USD Million (2013-2018)
  • Table 85. North America Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 86. United States Cannabidiol, by Type USD Million (2013-2018)
  • Table 87. United States Cannabidiol, by Application USD Million (2013-2018)
  • Table 88. United States Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 89. Canada Cannabidiol, by Type USD Million (2013-2018)
  • Table 90. Canada Cannabidiol, by Application USD Million (2013-2018)
  • Table 91. Canada Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 92. Mexico Cannabidiol, by Type USD Million (2013-2018)
  • Table 93. Mexico Cannabidiol, by Application USD Million (2013-2018)
  • Table 94. Mexico Cannabidiol, by Disease Indication USD Million (2013-2018)
  • Table 95. Cannabidiol Sales: by Type(K tons)
  • Table 96. Cannabidiol Sales Food Grade , by Region K tons (2013-2018)
  • Table 97. Cannabidiol Sales Pharmaceutical Grade , by Region K tons (2013-2018)
  • Table 98. Cannabidiol Sales: by Application(K tons)
  • Table 99. Cannabidiol Sales Medical , by Region K tons (2013-2018)
  • Table 100. Cannabidiol Sales Recreational , by Region K tons (2013-2018)
  • Table 101. Cannabidiol Sales: by Disease Indication(K tons)
  • Table 102. Cannabidiol Sales Anxiety , by Region K tons (2013-2018)
  • Table 103. Cannabidiol Sales Fibromyalgia (FM) , by Region K tons (2013-2018)
  • Table 104. Cannabidiol Sales Diabetes , by Region K tons (2013-2018)
  • Table 105. Cannabidiol Sales Other , by Region K tons (2013-2018)
  • Table 106. South America Cannabidiol Sales, by Country K tons (2013-2018)
  • Table 107. South America Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 108. South America Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 109. South America Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 110. Brazil Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 111. Brazil Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 112. Brazil Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 113. Argentina Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 114. Argentina Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 115. Argentina Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 116. Rest of South America Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 117. Rest of South America Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 118. Rest of South America Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 119. Asia Pacific Cannabidiol Sales, by Country K tons (2013-2018)
  • Table 120. Asia Pacific Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 121. Asia Pacific Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 122. Asia Pacific Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 123. China Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 124. China Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 125. China Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 126. Japan Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 127. Japan Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 128. Japan Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 129. India Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 130. India Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 131. India Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 132. South Korea Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 133. South Korea Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 134. South Korea Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 135. Taiwan Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 136. Taiwan Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 137. Taiwan Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 138. Australia Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 139. Australia Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 140. Australia Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 141. Rest of Asia-Pacific Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 142. Rest of Asia-Pacific Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 143. Rest of Asia-Pacific Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 144. Europe Cannabidiol Sales, by Country K tons (2013-2018)
  • Table 145. Europe Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 146. Europe Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 147. Europe Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 148. Germany Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 149. Germany Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 150. Germany Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 151. France Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 152. France Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 153. France Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 154. Italy Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 155. Italy Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 156. Italy Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 157. United Kingdom Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 158. United Kingdom Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 159. United Kingdom Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 160. Netherlands Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 161. Netherlands Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 162. Netherlands Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 163. Rest of Europe Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 164. Rest of Europe Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 165. Rest of Europe Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 166. MEA Cannabidiol Sales, by Country K tons (2013-2018)
  • Table 167. MEA Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 168. MEA Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 169. MEA Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 170. Middle East Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 171. Middle East Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 172. Middle East Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 173. Africa Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 174. Africa Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 175. Africa Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 176. North America Cannabidiol Sales, by Country K tons (2013-2018)
  • Table 177. North America Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 178. North America Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 179. North America Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 180. United States Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 181. United States Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 182. United States Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 183. Canada Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 184. Canada Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 185. Canada Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 186. Mexico Cannabidiol Sales, by Type K tons (2013-2018)
  • Table 187. Mexico Cannabidiol Sales, by Application K tons (2013-2018)
  • Table 188. Mexico Cannabidiol Sales, by Disease Indication K tons (2013-2018)
  • Table 189. Cannabidiol: by Type(USD/Units)
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Cannabidiol: by Type(USD Million)
  • Table 201. Cannabidiol Food Grade , by Region USD Million (2019-2024)
  • Table 202. Cannabidiol Pharmaceutical Grade , by Region USD Million (2019-2024)
  • Table 203. Cannabidiol: by Application(USD Million)
  • Table 204. Cannabidiol Medical , by Region USD Million (2019-2024)
  • Table 205. Cannabidiol Recreational , by Region USD Million (2019-2024)
  • Table 206. Cannabidiol: by Disease Indication(USD Million)
  • Table 207. Cannabidiol Anxiety , by Region USD Million (2019-2024)
  • Table 208. Cannabidiol Fibromyalgia (FM) , by Region USD Million (2019-2024)
  • Table 209. Cannabidiol Diabetes , by Region USD Million (2019-2024)
  • Table 210. Cannabidiol Other , by Region USD Million (2019-2024)
  • Table 211. South America Cannabidiol, by Country USD Million (2019-2024)
  • Table 212. South America Cannabidiol, by Type USD Million (2019-2024)
  • Table 213. South America Cannabidiol, by Application USD Million (2019-2024)
  • Table 214. South America Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 215. Brazil Cannabidiol, by Type USD Million (2019-2024)
  • Table 216. Brazil Cannabidiol, by Application USD Million (2019-2024)
  • Table 217. Brazil Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 218. Argentina Cannabidiol, by Type USD Million (2019-2024)
  • Table 219. Argentina Cannabidiol, by Application USD Million (2019-2024)
  • Table 220. Argentina Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 221. Rest of South America Cannabidiol, by Type USD Million (2019-2024)
  • Table 222. Rest of South America Cannabidiol, by Application USD Million (2019-2024)
  • Table 223. Rest of South America Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 224. Asia Pacific Cannabidiol, by Country USD Million (2019-2024)
  • Table 225. Asia Pacific Cannabidiol, by Type USD Million (2019-2024)
  • Table 226. Asia Pacific Cannabidiol, by Application USD Million (2019-2024)
  • Table 227. Asia Pacific Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 228. China Cannabidiol, by Type USD Million (2019-2024)
  • Table 229. China Cannabidiol, by Application USD Million (2019-2024)
  • Table 230. China Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 231. Japan Cannabidiol, by Type USD Million (2019-2024)
  • Table 232. Japan Cannabidiol, by Application USD Million (2019-2024)
  • Table 233. Japan Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 234. India Cannabidiol, by Type USD Million (2019-2024)
  • Table 235. India Cannabidiol, by Application USD Million (2019-2024)
  • Table 236. India Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 237. South Korea Cannabidiol, by Type USD Million (2019-2024)
  • Table 238. South Korea Cannabidiol, by Application USD Million (2019-2024)
  • Table 239. South Korea Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 240. Taiwan Cannabidiol, by Type USD Million (2019-2024)
  • Table 241. Taiwan Cannabidiol, by Application USD Million (2019-2024)
  • Table 242. Taiwan Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 243. Australia Cannabidiol, by Type USD Million (2019-2024)
  • Table 244. Australia Cannabidiol, by Application USD Million (2019-2024)
  • Table 245. Australia Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 246. Rest of Asia-Pacific Cannabidiol, by Type USD Million (2019-2024)
  • Table 247. Rest of Asia-Pacific Cannabidiol, by Application USD Million (2019-2024)
  • Table 248. Rest of Asia-Pacific Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 249. Europe Cannabidiol, by Country USD Million (2019-2024)
  • Table 250. Europe Cannabidiol, by Type USD Million (2019-2024)
  • Table 251. Europe Cannabidiol, by Application USD Million (2019-2024)
  • Table 252. Europe Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 253. Germany Cannabidiol, by Type USD Million (2019-2024)
  • Table 254. Germany Cannabidiol, by Application USD Million (2019-2024)
  • Table 255. Germany Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 256. France Cannabidiol, by Type USD Million (2019-2024)
  • Table 257. France Cannabidiol, by Application USD Million (2019-2024)
  • Table 258. France Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 259. Italy Cannabidiol, by Type USD Million (2019-2024)
  • Table 260. Italy Cannabidiol, by Application USD Million (2019-2024)
  • Table 261. Italy Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 262. United Kingdom Cannabidiol, by Type USD Million (2019-2024)
  • Table 263. United Kingdom Cannabidiol, by Application USD Million (2019-2024)
  • Table 264. United Kingdom Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 265. Netherlands Cannabidiol, by Type USD Million (2019-2024)
  • Table 266. Netherlands Cannabidiol, by Application USD Million (2019-2024)
  • Table 267. Netherlands Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 268. Rest of Europe Cannabidiol, by Type USD Million (2019-2024)
  • Table 269. Rest of Europe Cannabidiol, by Application USD Million (2019-2024)
  • Table 270. Rest of Europe Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 271. MEA Cannabidiol, by Country USD Million (2019-2024)
  • Table 272. MEA Cannabidiol, by Type USD Million (2019-2024)
  • Table 273. MEA Cannabidiol, by Application USD Million (2019-2024)
  • Table 274. MEA Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 275. Middle East Cannabidiol, by Type USD Million (2019-2024)
  • Table 276. Middle East Cannabidiol, by Application USD Million (2019-2024)
  • Table 277. Middle East Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 278. Africa Cannabidiol, by Type USD Million (2019-2024)
  • Table 279. Africa Cannabidiol, by Application USD Million (2019-2024)
  • Table 280. Africa Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 281. North America Cannabidiol, by Country USD Million (2019-2024)
  • Table 282. North America Cannabidiol, by Type USD Million (2019-2024)
  • Table 283. North America Cannabidiol, by Application USD Million (2019-2024)
  • Table 284. North America Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 285. United States Cannabidiol, by Type USD Million (2019-2024)
  • Table 286. United States Cannabidiol, by Application USD Million (2019-2024)
  • Table 287. United States Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 288. Canada Cannabidiol, by Type USD Million (2019-2024)
  • Table 289. Canada Cannabidiol, by Application USD Million (2019-2024)
  • Table 290. Canada Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 291. Mexico Cannabidiol, by Type USD Million (2019-2024)
  • Table 292. Mexico Cannabidiol, by Application USD Million (2019-2024)
  • Table 293. Mexico Cannabidiol, by Disease Indication USD Million (2019-2024)
  • Table 294. Cannabidiol Sales: by Type(K tons)
  • Table 295. Cannabidiol Sales Food Grade , by Region K tons (2019-2024)
  • Table 296. Cannabidiol Sales Pharmaceutical Grade , by Region K tons (2019-2024)
  • Table 297. Cannabidiol Sales: by Application(K tons)
  • Table 298. Cannabidiol Sales Medical , by Region K tons (2019-2024)
  • Table 299. Cannabidiol Sales Recreational , by Region K tons (2019-2024)
  • Table 300. Cannabidiol Sales: by Disease Indication(K tons)
  • Table 301. Cannabidiol Sales Anxiety , by Region K tons (2019-2024)
  • Table 302. Cannabidiol Sales Fibromyalgia (FM) , by Region K tons (2019-2024)
  • Table 303. Cannabidiol Sales Diabetes , by Region K tons (2019-2024)
  • Table 304. Cannabidiol Sales Other , by Region K tons (2019-2024)
  • Table 305. South America Cannabidiol Sales, by Country K tons (2019-2024)
  • Table 306. South America Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 307. South America Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 308. South America Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 309. Brazil Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 310. Brazil Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 311. Brazil Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 312. Argentina Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 313. Argentina Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 314. Argentina Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 315. Rest of South America Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 316. Rest of South America Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 317. Rest of South America Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 318. Asia Pacific Cannabidiol Sales, by Country K tons (2019-2024)
  • Table 319. Asia Pacific Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 320. Asia Pacific Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 321. Asia Pacific Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 322. China Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 323. China Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 324. China Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 325. Japan Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 326. Japan Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 327. Japan Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 328. India Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 329. India Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 330. India Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 331. South Korea Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 332. South Korea Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 333. South Korea Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 334. Taiwan Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 335. Taiwan Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 336. Taiwan Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 337. Australia Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 338. Australia Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 339. Australia Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 340. Rest of Asia-Pacific Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 341. Rest of Asia-Pacific Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 342. Rest of Asia-Pacific Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 343. Europe Cannabidiol Sales, by Country K tons (2019-2024)
  • Table 344. Europe Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 345. Europe Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 346. Europe Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 347. Germany Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 348. Germany Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 349. Germany Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 350. France Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 351. France Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 352. France Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 353. Italy Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 354. Italy Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 355. Italy Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 356. United Kingdom Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 357. United Kingdom Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 358. United Kingdom Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 359. Netherlands Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 360. Netherlands Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 361. Netherlands Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 362. Rest of Europe Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 363. Rest of Europe Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 364. Rest of Europe Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 365. MEA Cannabidiol Sales, by Country K tons (2019-2024)
  • Table 366. MEA Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 367. MEA Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 368. MEA Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 369. Middle East Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 370. Middle East Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 371. Middle East Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 372. Africa Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 373. Africa Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 374. Africa Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 375. North America Cannabidiol Sales, by Country K tons (2019-2024)
  • Table 376. North America Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 377. North America Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 378. North America Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 379. United States Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 380. United States Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 381. United States Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 382. Canada Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 383. Canada Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 384. Canada Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 385. Mexico Cannabidiol Sales, by Type K tons (2019-2024)
  • Table 386. Mexico Cannabidiol Sales, by Application K tons (2019-2024)
  • Table 387. Mexico Cannabidiol Sales, by Disease Indication K tons (2019-2024)
  • Table 388. Cannabidiol: by Type(USD/Units)
  • Table 389. Research Programs/Design for This Report
  • Table 390. Key Data Information from Secondary Sources
  • Table 391. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cannabidiol: by Type USD Million (2013-2018)
  • Figure 5. Global Cannabidiol: by Application USD Million (2013-2018)
  • Figure 6. Global Cannabidiol: by Disease Indication USD Million (2013-2018)
  • Figure 7. South America Cannabidiol Share (%), by Country
  • Figure 8. Asia Pacific Cannabidiol Share (%), by Country
  • Figure 9. Europe Cannabidiol Share (%), by Country
  • Figure 10. MEA Cannabidiol Share (%), by Country
  • Figure 11. North America Cannabidiol Share (%), by Country
  • Figure 12. Global Cannabidiol: by Type K tons (2013-2018)
  • Figure 13. Global Cannabidiol: by Application K tons (2013-2018)
  • Figure 14. Global Cannabidiol: by Disease Indication K tons (2013-2018)
  • Figure 15. South America Cannabidiol Share (%), by Country
  • Figure 16. Asia Pacific Cannabidiol Share (%), by Country
  • Figure 17. Europe Cannabidiol Share (%), by Country
  • Figure 18. MEA Cannabidiol Share (%), by Country
  • Figure 19. North America Cannabidiol Share (%), by Country
  • Figure 20. Global Cannabidiol: by Type USD/Units (2013-2018)
  • Figure 21. Global Cannabidiol share by Players 2018 (%)
  • Figure 22. Global Cannabidiol share by Players (Top 3) 2018(%)
  • Figure 23. Global Cannabidiol share by Players (Top 5) 2018(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. ENDOCA BV (Netherlands) Revenue, Net Income and Gross profit
  • Figure 26. ENDOCA BV (Netherlands) Revenue: by Geography 2018
  • Figure 27. CBD American Shaman (United States) Revenue, Net Income and Gross profit
  • Figure 28. CBD American Shaman (United States) Revenue: by Geography 2018
  • Figure 29. Isodiol International Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 30. Isodiol International Inc. (Canada) Revenue: by Geography 2018
  • Figure 31. Medical Marijuana Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Medical Marijuana Inc. (United States) Revenue: by Geography 2018
  • Figure 33. Aurora Cannabis Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 34. Aurora Cannabis Inc. (Canada) Revenue: by Geography 2018
  • Figure 35. Cannoid LLC (United States) Revenue, Net Income and Gross profit
  • Figure 36. Cannoid LLC (United States) Revenue: by Geography 2018
  • Figure 37. Canopy Growth Corporation (Canada) Revenue, Net Income and Gross profit
  • Figure 38. Canopy Growth Corporation (Canada) Revenue: by Geography 2018
  • Figure 39. CV Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. CV Sciences, Inc. (United States) Revenue: by Geography 2018
  • Figure 41. Elixinol LLC (United States) Revenue, Net Income and Gross profit
  • Figure 42. Elixinol LLC (United States) Revenue: by Geography 2018
  • Figure 43. NuLeaf Naturals, LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 44. NuLeaf Naturals, LLC. (United States) Revenue: by Geography 2018
  • Figure 45. Global Cannabidiol: by Type USD Million (2019-2024)
  • Figure 46. Global Cannabidiol: by Application USD Million (2019-2024)
  • Figure 47. Global Cannabidiol: by Disease Indication USD Million (2019-2024)
  • Figure 48. South America Cannabidiol Share (%), by Country
  • Figure 49. Asia Pacific Cannabidiol Share (%), by Country
  • Figure 50. Europe Cannabidiol Share (%), by Country
  • Figure 51. MEA Cannabidiol Share (%), by Country
  • Figure 52. North America Cannabidiol Share (%), by Country
  • Figure 53. Global Cannabidiol: by Type K tons (2019-2024)
  • Figure 54. Global Cannabidiol: by Application K tons (2019-2024)
  • Figure 55. Global Cannabidiol: by Disease Indication K tons (2019-2024)
  • Figure 56. South America Cannabidiol Share (%), by Country
  • Figure 57. Asia Pacific Cannabidiol Share (%), by Country
  • Figure 58. Europe Cannabidiol Share (%), by Country
  • Figure 59. MEA Cannabidiol Share (%), by Country
  • Figure 60. North America Cannabidiol Share (%), by Country
  • Figure 61. Global Cannabidiol: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • ENDOCA BV (Netherlands)
  • CBD American Shaman (United States)
  • Isodiol International Inc. (Canada)
  • Medical Marijuana Inc. (United States)
  • Aurora Cannabis Inc. (Canada)
  • Cannoid LLC (United States)
  • Canopy Growth Corporation (Canada)
  • CV Sciences, Inc. (United States)
  • Elixinol LLC (United States)
  • NuLeaf Naturals, LLC. (United States)
Additional players considered in the study are as follows:
FOLIUM BIOSCIENCES (United States) , Green Roads Wellness (United States) , Kazmira LLC (Orochem Technologies) (United States) , Charlotte's Web (CWB Holdings, Inc.) (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation